Baidu
map

Diabetes Care:血浆和肽素是1型糖尿病患者的冠心病风险的预测指标

2016-10-11 MedSci MedSci原创

一项基于人群的研究表明,可替代血管加压素的血浆和肽素,与肾功能下降和蛋白尿有关,还与2型糖尿病患者的糖尿病肾病进展有关。 我们对1型糖尿病患者进行了研究,评估肾脏和心血管事件以及全因死亡率风险与血浆和肽素之间的关联。 研究纳入了两个队列GENEDIAB队列(n = 398;男性占56%,平均± SD年龄 45 ± 12岁,糖尿病病程28 ± 10年)和GENESIS队列(n = 588

一项基于人群的研究表明,可替代血管加压素的血浆和肽素,与肾功能下降和蛋白尿有关,还与2型糖尿病患者的糖尿病肾病进展有关。

我们对1型糖尿病患者进行了研究,评估肾脏和心血管事件以及全因死亡率风险与血浆和肽素之间的关联。

研究纳入了两个队列GENEDIAB队列(n = 398;男性占56%,平均± SD年龄 45 ± 12岁,糖尿病病程28 ± 10年)和GENESIS队列(n = 588;男性占52%,平均± SD年龄 42 ± 11岁,糖尿病病程27 ± 9年);两组队列分别有218人和518人有可用的随访数据;中位数随访时间分别为10.2年和5年。

校正性别、性别、糖尿病病程、队列成员后,合并数据分析结果显示,将性别特异性血浆和肽素浓度三等分,浓度越高,随访期间的终末期肾病(ESRD)风险越高(最高三分之一组与最低三分之一组比较:HR=26.5 [95% CI 8.0–163.3; P < 0.0001])。

此外,血浆和肽素浓度越高,随访期间的心肌梗死或冠状动脉血运重建术(HR 2.2 [95% CI 1.2–4.0]; P = 0.01)、以及死亡率(HR 3.3 [95% CI 1.8–6.5]; P < 0.0001)风险越高。

血浆和肽素是1型糖尿病患者ESRD、冠心病和全因死亡率的风险预测因素。本研究数据与实验和流行病学研究的数据结果是一致的,表明高循环水平的抗利尿激素对肾功能是有害的。

原始出处:

Gilberto Velho,et al.Plasma Copeptin, Kidney Outcomes, Ischemic Heart Disease, and All-Cause Mortality in People With Long-Standing Type 1 Diabetes.Diabetes Care 2016 Oct;

本文系梅斯医学(MedSci)原 创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
    2017-05-06 laymankey

    感谢分享一下!!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
    2016-10-15 仁者大医
  6. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
    2016-10-15 1de48adem68(暂无匿称)

    可以参考,以后模范做类似课题

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1901470, encodeId=0e2819014e0cc, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Sep 03 21:37:00 CST 2017, time=2017-09-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1968202, encodeId=f4fd19682022e, content=<a href='/topic/show?id=a4b96e542' target=_blank style='color:#2F92EE;'>#1型糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=675, encryptionId=a4b96e542, topicName=1型糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0e3195, createdName=millore, createdTime=Tue Apr 04 00:37:00 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1770992, encodeId=676f1e70992a2, content=<a href='/topic/show?id=5572308336a' target=_blank style='color:#2F92EE;'>#冠心病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30833, encryptionId=5572308336a, topicName=冠心病风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfc938196115, createdName=hbwxf, createdTime=Wed Nov 16 20:37:00 CST 2016, time=2016-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=194625, encodeId=942e19462576, content=感谢分享一下!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=114, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Sat May 06 15:08:17 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759781, encodeId=17111e59781af, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sat Oct 15 04:37:00 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1637502, encodeId=b1b0163e502f9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Jan 07 20:37:00 CST 2017, time=2017-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148552, encodeId=5fc2148552f4, content=可以参考,以后模范做类似课题, beContent=null, objectType=article, channel=null, level=null, likeNumber=122, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTI9X140JXPuaKWWY7pcpOQCp6jSFssJq9bMmib99rYzz8SfbLfY5pUjllibm9p9j97e04VpDTJCq8uw/132, createdBy=5a171686354, createdName=1de48adem68(暂无匿称), createdTime=Sat Oct 15 11:28:29 CST 2016, time=2016-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1406994, encodeId=6fbe1406994b1, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1443398, encodeId=d3551443398d0, content=<a href='/topic/show?id=1a8e39e6574' target=_blank style='color:#2F92EE;'>#和肽素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39765, encryptionId=1a8e39e6574, topicName=和肽素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d025064673, createdName=12498e87m40暂无昵称, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1474077, encodeId=8f3c14e407764, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Thu Oct 13 13:37:00 CST 2016, time=2016-10-13, status=1, ipAttribution=)]

相关资讯

Neurology:和肽素有助判断缺血性卒中的预后

和肽素能够独立预测功能转归和死亡率 和肽素增高相比于那些已经确定的临床变量在预测转归和并发症上的作用尚不清楚。为此,瑞典伯尔尼大学神经内科的Gian Marco De Marchis博士等人进行了一项研究。研究结果在线发表在2013年3月6日的Neurology杂志上。研究结果显示:对于缺血性卒中患者,和肽素是除了卒中严重程度和年龄之外能够增加功能转归和3个月死亡预测效力的实用血液标志物。该研究

EJEM:和肽素(copeptin)或可用作急性冠脉综合征的生物标记物

      科学家最近发现一种名为和肽素的物质可以作为急性冠脉综合症非常有效的生物标记物。通过和肽素监测,研究人员可以迅速确定患者是否为心脏病发作。一项有902人参与的临床研究显示,通过和肽素检测方法可以大大提高心脏病确诊的准确性。 一位英国的医生表示,在医院中有类似胸口疼痛等心脏病疑似症状的患者中大概只有10%真正患有急性心脏病。这一生物标记物如能应用,将大大提高医院工

Endocr Pract:住院期间高钠血症会增加死亡风险?

老年住院患者中,伴有高钠血症与不伴高钠血症的患者相比,死亡率更高。 来自耶路撒冷Shaare Zedek医疗中心的Gabriel Munter博士和同事,对33名高钠血症(>70岁;入院时钠 > 150 meq/L)和30名非高钠血症的老年住院患者进行了研究。 收集参与者入院时的人口、功能和临床数据,以及血清和肽素水平(作为抗利尿激素分泌的标志物)。出院后随访30天。主要终点为死

Acta Neurol Scand:和肽素水平较高是TIA患者再发卒中的预测因素

背景:临床上,根据临床数据及血管影像学处理短暂性脑缺血(TIA),然而,一些生物标记物也能改善TIA患者的预后。方法:评估症状开始第一个24h内TIA患者血清和肽素,脂联素,新蝶呤,神经元特异性烯醇化酶,超敏C反应蛋白,IL-6,钠尿肽,S100β,肿瘤坏死因子-α和IL-1α水平以及患者临床特征。结果:在237名TIA患者中,12名(5%)患者7天内发生卒中,14名(6%)90天内发生卒中。分析

Stroke:和肽素可预测缺血性卒中患者血管事件的再发

背景和目的:和肽素作为精氨酸加压素原羧基末端的一部分,是心肌梗死和心衰患者预后的有用的标记物。高水平的和肽素与缺血性卒中和短暂性脑缺血发作(TIA)不良功能预后和死亡率升高相关。然而,和肽素是否能预测TIA和卒中后发生血管事件的风险尚不清楚。方法:招募了从2002年到2007年牛津血管研究中TIA或缺血性卒中患者,检测和肽素水平,并随访到2014年。应用Cox回归分析相关的再发血管事件的风险。结果

Baidu
map
Baidu
map
Baidu
map